FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310125649> ?p ?o ?g. }

• W4310125649 endingPage "9503" @default.
• W4310125649 startingPage "9501" @default.
• W4310125649 abstract "Introduction. Treatment of relapsed-refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBCL) has changed substantially in recent years, due to the incorporation (in a commercial setting or in the context of clinical trials) of new therapeutic options such as new monoclonal antibodies (MA), antibody-drug conjugates (ADC), bispecific antibodies (BA) or CAR-T cell therapy. The main objective of our study was to evaluate the frequency of use of these new therapies (NT) in Spain, and their impact on overall survival (OS). Methods. This is a multicenter retrospective study. Patients with DLBCL and HGBCL were identified from the RELINF platform, where GELTAMO investigators register all patients with lymphoma diagnosed in each center from January 2014. Finally, 15 centers (2 out of 15 CAR-T cell providers) accepted to participate in the study, who were asked to complete additional information related with relapse and NT. Patients were divided in 2 cohorts according to date of documentation of relapse / refractory disease: 2014-2017 (first period) and 2018-2021 (second period). The use of NT in both periods and their impact on OS were analyzed. Results We included 2162 patients in the analysis, 1891 DLBCL (51% germinal centre B-cell phenotype, 41% activated B-cell phenotype, 8% indeterminate), and 271 HGBCL (45% of them double/triple hit). Median age was 69 y/o, 72% were ≥ 70 y/o at diagnosis, and 49.8% were female. Four hundred and ninety four patients had relapsed or refractory disease, 183 in the 1st period, and 311 in the 2nd period. Median number of lines for r/r patients was 3 (2-7). NT were used in 353 patients, 30 in the 1st period and 111 in the 2nd period. New MA were used in 88 (28%) patients, being polatuzumab vedotin the most frequently used antibody (47, 54%) (tafasitamab 7, loncastuximab 5, brentuximab 11, others 10), and BA in 28 (9%), all of them within clinical trials. Twenty patients received NT in 1st relapse, 14 MA and 7 BA. From 211 patients who received > 2 lines of treatment, 128 were in the 2nd period, and 60 (47%) of them received CAR-T cell therapy, whereas 39 (30%) of these patients did not receive any NT. Five-year progression free survival (PFS) for the entire cohort was 71% (95% CI 69-74), and median overall survival (OS) was 90 months (95% CI: 76-NR). Median OS for r/r patients was 22 months (95% CI: 19 - 26), and for the group of patients who received > 2 lines was 23 months (95% CI; 19-27). With a median follow up of 25 months (50 months for the 1st period and 20 months for the 2nd period) OS was superior for patients relapsed in the 2nd period (26 months [95% CI: 22-38]), compared with those relapsed in the 1st period (18 months [IC: 16-22], p= 0.016) (Figure 1, A). Median OS since first relapse for patients pre-treated with > 2 lines who received CAR-T cells was 31 months vs 11 months for patients who did not receive CART (p= 0.002) (Figure 1, B). Conclusion: The OS of patients with r/r DLBCL and HGBCL has improved in recent years, probably in relation to the incorporation of NT, although the use of these NT in Spain has been lower than expected for this population. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310125649 created "2022-11-30" @default.
• W4310125649 creator A5006538688 @default.
• W4310125649 creator A5016510706 @default.
• W4310125649 creator A5020921101 @default.
• W4310125649 creator A5023818951 @default.
• W4310125649 creator A5026046034 @default.
• W4310125649 creator A5027157907 @default.
• W4310125649 creator A5034504372 @default.
• W4310125649 creator A5034861019 @default.
• W4310125649 creator A5038185841 @default.
• W4310125649 creator A5039114491 @default.
• W4310125649 creator A5046760522 @default.
• W4310125649 creator A5071331756 @default.
• W4310125649 creator A5074540960 @default.
• W4310125649 creator A5074962085 @default.
• W4310125649 creator A5077730260 @default.
• W4310125649 creator A5080587560 @default.
• W4310125649 date "2022-11-15" @default.
• W4310125649 modified "2023-10-18" @default.
• W4310125649 title "Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group" @default.
• W4310125649 doi "https://doi.org/10.1182/blood-2022-166213" @default.
• W4310125649 hasPublicationYear "2022" @default.
• W4310125649 type Work @default.
• W4310125649 citedByCount "0" @default.
• W4310125649 crossrefType "journal-article" @default.
• W4310125649 hasAuthorship W4310125649A5006538688 @default.
• W4310125649 hasAuthorship W4310125649A5016510706 @default.
• W4310125649 hasAuthorship W4310125649A5020921101 @default.
• W4310125649 hasAuthorship W4310125649A5023818951 @default.
• W4310125649 hasAuthorship W4310125649A5026046034 @default.
• W4310125649 hasAuthorship W4310125649A5027157907 @default.
• W4310125649 hasAuthorship W4310125649A5034504372 @default.
• W4310125649 hasAuthorship W4310125649A5034861019 @default.
• W4310125649 hasAuthorship W4310125649A5038185841 @default.
• W4310125649 hasAuthorship W4310125649A5039114491 @default.
• W4310125649 hasAuthorship W4310125649A5046760522 @default.
• W4310125649 hasAuthorship W4310125649A5071331756 @default.
• W4310125649 hasAuthorship W4310125649A5074540960 @default.
• W4310125649 hasAuthorship W4310125649A5074962085 @default.
• W4310125649 hasAuthorship W4310125649A5077730260 @default.
• W4310125649 hasAuthorship W4310125649A5080587560 @default.
• W4310125649 hasBestOaLocation W43101256491 @default.
• W4310125649 hasConcept C126322002 @default.
• W4310125649 hasConcept C142424586 @default.
• W4310125649 hasConcept C143998085 @default.
• W4310125649 hasConcept C2778559949 @default.
• W4310125649 hasConcept C2779338263 @default.
• W4310125649 hasConcept C2780653079 @default.
• W4310125649 hasConcept C2781214270 @default.
• W4310125649 hasConcept C71924100 @default.
• W4310125649 hasConcept C86803240 @default.
• W4310125649 hasConcept C87355193 @default.
• W4310125649 hasConceptScore W4310125649C126322002 @default.
• W4310125649 hasConceptScore W4310125649C142424586 @default.
• W4310125649 hasConceptScore W4310125649C143998085 @default.
• W4310125649 hasConceptScore W4310125649C2778559949 @default.
• W4310125649 hasConceptScore W4310125649C2779338263 @default.
• W4310125649 hasConceptScore W4310125649C2780653079 @default.
• W4310125649 hasConceptScore W4310125649C2781214270 @default.
• W4310125649 hasConceptScore W4310125649C71924100 @default.
• W4310125649 hasConceptScore W4310125649C86803240 @default.
• W4310125649 hasConceptScore W4310125649C87355193 @default.
• W4310125649 hasIssue "Supplement 1" @default.
• W4310125649 hasLocation W43101256491 @default.
• W4310125649 hasOpenAccess W4310125649 @default.
• W4310125649 hasPrimaryLocation W43101256491 @default.
• W4310125649 hasRelatedWork W2006704637 @default.
• W4310125649 hasRelatedWork W2073532400 @default.
• W4310125649 hasRelatedWork W2110119190 @default.
• W4310125649 hasRelatedWork W2948321946 @default.
• W4310125649 hasRelatedWork W2980045240 @default.
• W4310125649 hasRelatedWork W3166781690 @default.
• W4310125649 hasRelatedWork W3216087164 @default.
• W4310125649 hasRelatedWork W4283391970 @default.
• W4310125649 hasRelatedWork W4313491845 @default.
• W4310125649 hasRelatedWork W2404372762 @default.
• W4310125649 hasVolume "140" @default.
• W4310125649 isParatext "false" @default.
• W4310125649 isRetracted "false" @default.
• W4310125649 workType "article" @default.